Formulation of a geldanamycin prodrug in mPEG-b-PCL micelles greatly enhances tolerability and pharmacokinetics in rats

Journal of Controlled Release

Volumn 129, Issue 1, 2008, Pages 33-40

  Xiong, May P ^a   Yáñez, Jaime A ^b   Remsberg, Connie M ^b   Ohgami, Yusuke ^b   Kwon, Glen S ^c   Davies, Neal M ^b   Forrest, M Laird ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Free 17 DMAG (17 dimethylaminoethylamino 17 demethoxygeldanamycin); Geldanamycin prodrug; Pharmacokinetics; Poly(ethylene glycol) b poly( caprolactone); Polymeric micelle

Indexed keywords

MICELLES; PHARMACOKINETICS; POLYETHYLENE GLYCOLS;

GELDANAMYCIN PRODRUG; POLYMERIC MICELLES;

DRUG PRODUCTS;

17 BETA HYDROXYETHYLAMINO 17 DEMETHOXYGELDANAMYCIN; 17 DEMETHOXY 17 (2 DIMETHYLAMINOETHYLAMINO)GELDANAMYCIN; ALVESPIMYCIN; DRUG DERIVATIVE; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; MACROGOL; NANOCARRIER; POLYCAPROLACTONE; POLYETHYLENE GLYCOL BLOCK POLYCAPROLACTONE; PRODRUG; TANESPIMYCIN;

ANIMAL TISSUE; ARTICLE; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG FORMULATION; DRUG MECHANISM; DRUG SOLUBILITY; DRUG TOLERABILITY; ENCAPSULATION; LIPOPHILICITY; MALE; MAXIMUM TOLERATED DOSE; MICELLE; NONHUMAN; PRIORITY JOURNAL; RAT; SUSTAINED DRUG RELEASE; SYSTEMIC DISEASE; TOXICITY TESTING;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; AREA UNDER CURVE; BENZOQUINONES; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG COMPOUNDING; LACTAMS, MACROCYCLIC; MALE; MICELLES; POLYESTERS; POLYETHYLENE GLYCOLS; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; TECHNOLOGY, PHARMACEUTICAL; TISSUE DISTRIBUTION;

EID: 44649099522     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2008.03.015     Document Type: Article

References (40)

1. Roe S.M., Prodromou C., O'Brien R., Ladbury J.E., Piper P.W., and Pearl L.H. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J. Med. Chem. 42 2 (1999) 260-266
2. Goetz M.P., Toft D.O., Ames M.M., and Erlichman C. The Hsp90 chaperone complex as a novel target for cancer therapy. Ann. Oncol. 14 8 (2003) 1169-1176
3. Citri A., Kochupurakkal B.S., and Yarden Y. The achilles heel of ErbB-2/HER2: regulation by the Hsp90 chaperone machine and potential for pharmacological intervention. Cell Cycle 3 1 (2004) 51-60
4. Supko J.G., Hickman R.L., Grever M.R., and Malspeis L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother. Pharmacol. 36 4 (1995) 305-315
5. Ge J., Normant E., Porter J.R., Ali J.A., Dembski M.S., Gao Y., Georges A.T., Grenier L., Pak R.H., Patterson J., Sydor J.R., Tibbitts T.T., Tong J.K., Adams J., and Palombella V.J. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. J. Med. Chem. 49 15 (2006) 4606-4615
6. Sausville E.A., Tomaszewski J.E., and Ivy P. Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr. Cancer Drug Targets 3 5 (2003) 377-383
7. Dye D., and Watkins J. Suspected anaphylactic reaction to Cremophor EL. Br. Med. J. 280 6228 (1980) 1353
8. Geldanamycin Analogs. Development Therapeutics Program of the National Cancer Institute (2007) Bethesda, MD
9. Sydor J.R., Normant E., Pien C.S., Porter J.R., Ge J., Grenier L., Pak R.H., Ali J.A., Dembski M.S., Hudak J., Patterson J., Penders C., Pink M., Read M.A., Sang J., Woodward C., Zhang Y., Grayzel D.S., Wright J., Barrett J.A., Palombella V.J., Adams J., and Tong J.K. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc. Natl. Acad. Sci. U. S.A. 103 46 (2006) 17408-17413
10. Egorin M.J., Lagattuta T.F., Hamburger D.R., Covey J.M., White K.D., Musser S.M., and Eiseman J.L. Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats. Cancer Chemother. Pharmacol. 49 1 (2002) 7-19
11. Sausville E.A., Tomaszewski J.E., and Ivy P. Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr. Cancer Drug Targets 3 5 (2003) 377-383
12. Smith V., Sausville E.A., Camalier R.F., Fiebig H.H., and Burger A.M. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models. Cancer Chemother. Pharmacol. 56 2 (2005) 126-137
13. Kaur G., Belotti D., Burger A.M., Fisher-Nielson K., Borsotti P., Riccardi E., Thillainathan J., Hollingshead M., Sausville E.A., and Giavazzi R. Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator. Clin. Cancer Res. 10 14 (2004) 4813-4821
14. Glaze E.R., Lambert A.L., Smith A.C., Page J.G., Johnson W.D., McCormick D.L., Brown A.P., Levine B.S., Covey J.M., Egorin M.J., Eiseman J.L., Holleran J.L., Sausville E.A., and Tomaszewski J.E. Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance. Cancer Chemother. Pharmacol. 56 6 (2005) 637-647
15. Forrest M.L., Zhao A., Won C.Y., Malick A.W., and Kwon G.S. Lipophilic prodrugs of Hsp90 inhibitor geldanamycin for nanoencapsulation in poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelles. J. Control. Release (2006)
16. Forrest M.L., Won C.Y., Malick A.W., and Kwon G.S. In vitro release of the mTOR inhibitor rapamycin from poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelles. J. Control. Release 110 2 (2006) 370-377
17. Yamamoto T., Yokoyama M., Opanasopit P., Hayama A., Kawano K., and Maitani Y. What are determining factors for stable drug incorporation into polymeric micelle carriers? Consideration on physical and chemical characters of the micelle inner core. J. Control. Release 123 1 (2007) 11-18
18. Kwon G.S. Diblock copolymer nanoparticles for drug delivery. Crit. Rev. Ther. Drug Carr. Syst. 15 5 (1998) 481-512
19. Nishiyama N., and Kataoka K. Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol. Ther. 112 3 (2006) 630-648
20. Torchilin V.P. Structure and design of polymeric surfactant-based drug delivery systems. J. Control. Release 73 2-3 (2001) 137-172
21. Gaucher G., Dufresne M.H., Sant V.P., Kang N., Maysinger D., and Leroux J.C. Block copolymer micelles: preparation, characterization and application in drug delivery. J. Control. Release 109 1-3 (2005) 169-188
22. Kwon G.S., Yokoyama M., Okano T., Sakurai Y., and Kataoka K. Biodistribution of micelle-forming polymer-drug conjugates. Pharm. Res. 10 7 (1993) 970-974
23. Jette K.K., Law D., Schmitt E.A., and Kwon G.S. Preparation and drug loading of poly(ethylene glycol)-block-poly(epsilon-caprolactone) micelles through the evaporation of a cosolvent azeotrope. Pharm. Res. 21 7 (2004) 1184-1191
24. Aliabadi H.M., Mahmud A., Sharifabadi A.D., and Lavasanifar A. Micelles of methoxy poly(ethylene oxide)-b-poly(epsilon-caprolactone) as vehicles for the solubilization and controlled delivery of cyclosporine A. J. Control. Release 104 2 (2005) 301-311
25. Allen C., Han J., Yu Y., Maysinger D., and Eisenberg A. Polycaprolactone-b-poly(ethylene oxide) copolymer micelles as a delivery vehicle for dihydrotestosterone. J. Control. Release 63 3 (2000) 275-286
26. Woodward S.C., Brewer P.S., Moatamed F., Schindler A., and Pitt C.G. The intracellular degradation of poly(epsilon-caprolactone). J. Biomed. Mater. Res. 19 4 (1985) 437-444
27. Soo P., Luo L., Maysinger D., and Eisenberg A. Incorporation and release of hydrophobic probes in biocompatible polycaprolactone-block-poly(ethylene oxice) micelles: implications for drug delivery. Langmuir 18 (2002) 9996-10004
28. Park Y., Lee J., Chang Y., Jeong J., Chung J., Lee M., Park K., and Lee S. Radioisotope carrying polyethylene oxide-caprolactone copolymer micelles for targetable bone imaging. Biomaterials 23 (2003) 873-879
29. Liu J., Zeng F., and Allen C. In vivo fate of unimers and micelles of a poly(ethylene glycol)-block-poly(caprolactone) copolymer in mice following intravenous administration. Eur. J. Pharm. Biopharm. 65 3 (2007) 309-319
30. Savic R., Azzam T., Eisenberg A., and Maysinger D. Assessment of the integrity of poly(caprolactone)-b-poly(ethylene oxide) micelles under biological conditions: a fluorogenic-based approach. Langmuir 22 8 (2006) 3570-3578
31. Sasaki K., and Inoue Y. Geldanamycin derivatives and antitumor drug. US 4,261,989, April 14, 1981 (1980)
32. Shibasaki Y., Sanada H., Yokoi M., Sanda F., and Endo T. Activated monomer cationic polymerization of lactones and the application to well-defined block copolymer synthesis with seven-membered ring cyclic carbonate. Macromolecules 33 12 (2000) 4316-4320
33. Davies B., and Morris T. Physiological parameters in laboratory animals and humans. Pharm. Res. 10 7 (1993) 1093-1095
34. Aliabadi H.M., Brocks D.R., and Lavasanifar A. Polymeric micelles for the solubilization and delivery of cyclosporine A: pharmacokinetics and biodistribution. Biomaterials 26 35 (2005) 7251-7259
35. Versluis A.J., Rump E.T., Rensen P.C., Van Berkel T.J., and Bijsterbosch M.K. Synthesis of a lipophilic daunorubicin derivative and its incorporation into lipidic carriers developed for LDL receptor-mediated tumor therapy. Pharm. Res. 15 4 (1998) 531-537
36. Versluis A.J., Rump E.T., Rensen P.C., van Berkel T.J., and Bijsterbosch M.K. Stable incorporation of a lipophilic daunorubicin prodrug into apolipoprotein E-exposing liposomes induces uptake of prodrug via low-density lipoprotein receptor in vivo. J. Pharmacol. Exp. Ther. 289 1 (1999) 1-7
37. Hashida M., Sato K., Takakura Y., and Sezaki H. Characterization of a lipophilic prodrug of 5-fluorouracil with a cholesterol promoiety and its application to liposomes. Chem. Pharm. Bull. (Tokyo) 36 8 (1988) 3186-3189
38. Rodrigues D.G., Maria D.A., Fernandes D.C., Valduga C.J., Couto R.D., Ibanez O.C., and Maranhao R.C. Improvement of paclitaxel therapeutic index by derivatization and association to a cholesterol-rich microemulsion: in vitro and in vivo studies. Cancer Chemother. Pharmacol. 55 6 (2005) 565-576
39. Ritschel W.A., and Kearns G.L. Handbook of Basic Pharmacokinetics... Including Clinical Applications (2004), APhA Publications
40. Matsumura Y., and Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46 12 (1986) 6387-6392